EGFR and KRAS, the types of oncogenic drivers in NSCLC, can activate the PI3K/AKT/mTOR pathway, which enhances cancer cell proliferation, metabolism, and survival [184]. Here, AKT1 is linked to non-small cell lung carcinoma.